JP2015520142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520142A5 JP2015520142A5 JP2015510815A JP2015510815A JP2015520142A5 JP 2015520142 A5 JP2015520142 A5 JP 2015520142A5 JP 2015510815 A JP2015510815 A JP 2015510815A JP 2015510815 A JP2015510815 A JP 2015510815A JP 2015520142 A5 JP2015520142 A5 JP 2015520142A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- esmolol hydrochloride
- formulation
- ready
- saline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000243 solution Substances 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 claims 10
- 229960001015 esmolol hydrochloride Drugs 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000008215 water for injection Substances 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000008176 lyophilized powder Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 206010000489 Acidosis hyperchloraemic Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims 1
- 208000029422 Hypernatremia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 239000012891 Ringer solution Substances 0.000 claims 1
- 208000007888 Sinus Tachycardia Diseases 0.000 claims 1
- 206010040893 Skin necrosis Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002895 aortic dissection Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443.6 | 2012-05-10 | ||
| EP12167443 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520142A JP2015520142A (ja) | 2015-07-16 |
| JP2015520142A5 true JP2015520142A5 (https=) | 2016-06-09 |
| JP6220383B2 JP6220383B2 (ja) | 2017-10-25 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510815A Active JP6220383B2 (ja) | 2012-05-10 | 2013-05-08 | 非経口エスモロール製剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (https=) |
| EP (1) | EP2846776B1 (https=) |
| JP (1) | JP6220383B2 (https=) |
| CN (1) | CN104379134A (https=) |
| AU (1) | AU2013258031B2 (https=) |
| BR (1) | BR112014027870B1 (https=) |
| CA (1) | CA2872953C (https=) |
| CL (1) | CL2014003028A1 (https=) |
| DK (1) | DK2846776T3 (https=) |
| EA (1) | EA032344B1 (https=) |
| ES (1) | ES2794093T3 (https=) |
| HR (1) | HRP20200897T1 (https=) |
| HU (1) | HUE049314T2 (https=) |
| IL (1) | IL235497A0 (https=) |
| LT (1) | LT2846776T (https=) |
| MA (1) | MA37500B1 (https=) |
| MX (1) | MX374771B (https=) |
| MY (1) | MY173900A (https=) |
| NZ (1) | NZ701429A (https=) |
| PH (1) | PH12014502494B1 (https=) |
| PL (1) | PL2846776T3 (https=) |
| PT (1) | PT2846776T (https=) |
| SI (1) | SI2846776T1 (https=) |
| TN (1) | TN2014000464A1 (https=) |
| UA (1) | UA115333C2 (https=) |
| WO (1) | WO2013167657A1 (https=) |
| ZA (1) | ZA201408149B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (en) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | A lyophilisate comprising esmolol and adenosine for use in cardioplegia |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| HRP20121045T1 (hr) | 2007-12-21 | 2013-01-31 | Aop Orphan Pharmaceuticals Ag | Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 MX MX2014013556A patent/MX374771B/es active IP Right Grant
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/en not_active Ceased
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 HR HRP20200897TT patent/HRP20200897T1/hr unknown
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/en active Active
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
- 2013-05-08 CA CA2872953A patent/CA2872953C/en active Active
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2010511715A5 (https=) | ||
| ES2324009B1 (es) | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| JP2013537212A5 (https=) | ||
| RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
| MX2020010130A (es) | Formulacion y metodo de preparacion. | |
| FI2988750T4 (fi) | Landiololihydrokloridin käyttö takyarytmioiden pitkäaikaishoidossa | |
| TWI894333B (zh) | 血管收縮素ii受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用 | |
| JP2015520142A5 (https=) | ||
| CN103054883B (zh) | 一种含有果糖二磷酸钠化合物的药物组合物 | |
| TWI809313B (zh) | 血管緊張素ii受體拮抗劑代謝產物與nep抑制劑的複合物的新心衰用途 | |
| CN108815171B (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| HRP20200897T1 (hr) | Parenteralna formulacija esmolola | |
| RU2012116226A (ru) | Бронхолитическое средство на основе простагландина | |
| CN103340863A (zh) | 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用 | |
| WO2019152765A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and signaling | |
| CN109806263A (zh) | 一种药物组合物及其制备方法和用途 | |
| WO2022233310A1 (zh) | 丹酚酸a盐水合物、其制备方法及用途 | |
| CN116785435B (zh) | Ep3受体拮抗剂l-798106在制备预防心肌缺血再灌注损伤药物中的应用 | |
| JPWO2015020139A1 (ja) | ナノ粒子及びナノ粒子組成物並びにその製造方法 |